The long- term cardiovascular protection conferred by angiotensin-converting enzyme inhibitor-mediated was strongly supported by the results of the Heart Outcomes Prevention Evaluation (HOPE) trial, indicating a significant relative risk reduction in the combined endpoint of cardiovascular death, MI and stroke or cardiac arrest (Yusuf et al., 2000). The gene discussed is ACE; the disease is cardiac arrest.